This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Banas, J. S. Search for Related Content PubMed PubMed Citation Articles by Banas, J. S., JR. Social Bookmarking                   What's this?

Preliminary Hemodynamic Report of the Efficacy and Safety of Quinapril in Acute and Chronic Treatment of Patients with Congestive Heart Failure

NEW YORK, NEW YORK AND MORRISTOWN, NEW JERSEY, Chief of Morristown Memorial Hospital 100 Madison Ave. Morristown, NJ 07960

A two-part hemodynamic trial of the efficacy and safety of quinapril hydrochloride was conducted in 26 patients with congestive heart failure (NYHA Class III or IV) who had not optimally responded to treatment with diuretics and digitalis. A total of 25 patients had evaluable data after receiving single doses (2.5, 5, or 10 mg) of quinapril. Following acute dosing, favorable hemodynamic changes began within thirty minutes to one hour and usually reached a maximum within four hours post dose. Nineteen evaluable patients who had responded to acute therapy received an additional sixteen weeks of chronic treatment with quinapril in individualized dosage regimens. Hemodynamic responses did not dif fer markedly between acute and chronic therapy. Favorable hemody namic responses were maintained or enhanced following chronic doses of 5 to 30 mg/day (given either once daily or in divided doses). The most fre quent doses were 10-15 mg/day in di vided doses. The mean maximum percent changes in four primary he modynamic parameters after chronic dosing (compared with baseline) were: mean arterial blood pressure, -3.9%; pulmonary capillary wedge pressure, -39.7%; cardiac output, +31.7%; and systemic vascular re sistance, -25.2%. Changes in heart rate and mean arterial blood pres sure did not result in clinically signif icant bradycardia or hypotention. Overall, quinapril produced both acute and sustained beneficial hemo dynamic effects in patients whose congestive heart failure was not clini cally controlled with diuretics and digitalis.

Angiology, Vol. 40, No. 4 part_2, 396-404 (1989)
DOI: 10.1177/000331978904000409


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. C. Olson, A. M. Horvath, B. M. Michniewicz, A. J. Sedman, W. A. Colburn, P. G. Welling, and S. C. Olson The Clinical Pharmacokinetics of Quinapril Angiology, January 1, 1989; 40(4_part_2): 351 - 359. [Abstract] [PDF]